Dymista®
Dymista® var den første kombinasjonsnesesprayen (FP+AZE) på markedet, og den er tatt i bruk i mer enn 50 land1
Dymista® ble lansert som den første AR-behandlingen i sitt slag i Norge 2013. Siden den gang har
Dymista® blitt anerkjent som det foretrukne legemiddelet for behandling av allergisk rhinitt,
og har opparbeidet seg et rykte som et pålitelig produkt takket være god dokumentasjon.
Dymista® har meget god klinisk dokumentasjon med >10 000 pasienter2-17
- Klinisk dokumentert i fase III-studier med > 4 600 pasienter2,3,4
- Ytterligere 5 studier bekrefter den kliniske dokumentasjonen5-17, gjennomført etter lanseringen (inkl. >5 500 pasienter)
Dymista® er et globalt tilgjengelig produkt
- Først lansert i 20121
- Markedsført i mer enn 50 land på 5 kontinenter1
- Mer enn 50 millioner pakninger Dymista® er forskrevet verden over siden lanseringen1
Dymista® er godt dokumentert2-17
Dymista® er dobbelt så effektivt som INS*3
Dymista® har innsettende effekt etter 5 minutter16
Dymista® gir symptomkontroll (VAS<5) på mindre enn 3 dager5
70 % av pasientene var mer, eller mye mer, fornøyd med Dymista®, sammenlignet med sin tidligere allergi-behandling17
FP: flutikasonpropionat; AZE: azelastin; AR: allergisk rhinitt; INS: intranasalt steroid; VAS: visuell analog skala
Referanser:
- IQVIA, 2023.
- Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10.
- Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369-377.
- Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495-503.
- Klimek L, Bachert C, Mösges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36(1):40-47.
- Klimek L, Bachert C, Stjärne P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. Allergy Asthma Proc. 2016;37(5):376-386.
- Scadding G, Price D, El-Shanawany T, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open. 2017;7(4):e014777.
- Agache I, Doros IC, Leru PM, Bucur I, Poenaru M, Sarafoleanu C. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania. Rhinology. 2018;56(1):33-41.
- Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. Int Forum Allergy Rhinol. 2019;9(4):388-395.
- Kaulsay R, Nguyen DT, Kuhl HC. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immun Inflamm Dis. 2018;6(4):456-464.
- Pohl W, Kaulsay R, Stjärne P. Real life effectiveness of MP-AzeFlu® in persistent allergic rhinitis, assessed by visual analogue scale and endoscopy: pooled data from Austria, Ireland and Sweden. Posters presented at SERIN 2017.
- Stjarne P, Strand V, Theman K, Ehnhage A. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. Rhinology. 2019;57:279–86.
- Klimek L, Price D, Gálffy G, et al. Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study. Int Arch Allergy Immunol. 2020;181(10):754-764.
- Price D, Klimek L, Gálffy G, et al. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clin Mol Allergy. 2020;18:15.
- Van Weissenbruch R, Klimek L, Gálffy G, et al. MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis. J Asthma Allergy. 2020;13:633-645.
- Bousquet J, Meltzer EO, Couroux P, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-1732.e6.
- Canonica GW, Klimek L, Acaster S, et al. Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey. Curr Med Res Opin. 2021;37(7):1259-1272.
- Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence [published correction appears in J Allergy Clin Immunol. 2022 Jun;149(6):2180]. J Allergy Clin Immunol. 2020;145(1):70-80.e3.
DYM-2023-0876 | 01-2024
